News
ONVO
--
0.00%
--
Organovo Says Co Achieves 3D Tissue Model For Crohn's Disease
Organovo Holdings, Inc. (NASDAQ:ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announces that it has
Benzinga · 05/17 12:12
Organovo Holdings to Proceed With Target Discovery, Validation for Crohn's Disease After Achieving 3D Tissue Model
MT Newswires · 05/17 11:46
UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO (OTCPK: CLLKF, Nasdaq Stockholm: BICO.ST) announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundationa...
GlobeNewswire · 03/01 13:05
BRIEF-Organovo And BICO Reach Licensing Agreement On Bioprinting Patents
reuters.com · 02/23 14:17
Organovo, BICO reach licensing deal on bioprinting patents
Organovo (NASDAQ:ONVO) and BICO reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting. Organovo and BICO were engaged in
Seekingalpha · 02/23 14:14
Organovo Reports Licensing Deal On Bioprinting Patents With CELLINK, No Terms Disclosed
Organovo Holdings, Inc. (NASDAQ:ONVO), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting.
Benzinga · 02/23 13:14
Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting....
GlobeNewswire · 02/23 13:05
Organovo, BICO Reach Patent License Agreement for 3D Bioprinting
MT Newswires · 02/23 11:11
Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo”), today announced that it has granted a stock option to purchase 50,000 shares of common stock to one new employee. The stock option was granted pursuant to the...
GlobeNewswire · 02/18 21:00
10 3D Printing Companies to Watch in 2022
In this article, we discuss the 10 3D printing companies to watch in 2022. If you want to skip our detailed analysis of these companies, go directly to 5 3D Printing Companies to Watch in 2022. Thought of as something straight from a science fiction novel ...
Insider Monkey · 02/12 19:09
Cathie Wood Targets Illiquid Assets and Limits Exits in New Fund
(Bloomberg) -- Cathie Wood is upping her big bet on disruptive tech companies via a new fund targeting less-liquid markets with limits on how quickly investors can exit.Most Read from BloombergMeta Erases $251 Billion in Value, Biggest Wipeout in HistorySp...
Bloomberg · 02/04 14:06
BRIEF-Organovo Guides On Patent Portfolio And Successful Ipr Defense Of Two Patents
reuters.com · 02/02 17:45
Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that two of its patents have withstood a patent challenge, and the company provided guidance on how it expects to leverage its strong patent portfolio. Org...
GlobeNewswire · 02/02 17:00
Organovo Holdings' Patents Survive Petition With Patent Trial and Appeal Board
MT Newswires · 02/02 13:46
15 Worst Stock Picks of Cathie Wood
In this article, we discuss the 15 worst stock picks of Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to the 5 Worst Stock Picks of Cathie Wood. Cathie Wood, the chief ARK Investment Management, is often hailed as the ...
Insider Monkey · 01/21 16:37
61 Biggest Movers From Yesterday
Gainers Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa Immunogene combination therapy.
Benzinga · 01/04 10:06
Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 12/30/2021 14:24
Organovo Holdings Says On Track To Establish Human 3D Model In Inflammatory Bowel Disease In 2022
Organovo Holdings, Inc. (NASDAQ:ONVO), today provided a business overview and progress update, and announced it is on track to establish its first models of inflammatory bowel disease in 2022 using its 3D bioprinting and
Benzinga · 11/30/2021 13:10
50 Biggest Movers From Yesterday
Gainers
Benzinga · 11/30/2021 09:45
33 Stocks Moving In Monday's Mid-Day Session
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa (dy...
Benzinga · 11/29/2021 17:00
Webull provides a variety of real-time ONVO stock news. You can receive the latest news about Organovo Holding through multiple platforms. This information may help you make smarter investment decisions.
About ONVO
Organovo Holdings, Inc. is an early stage biotechnology company. The Company is focused on building high fidelity, three-dimensional (3D) tissues that recapitulate key aspects of human disease. The Company is targeting the intestine and has ongoing 3D tissue developments in Ulcerative colitis (UC) and Crohn's disease (CD). The Company uses its platform technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. NovoGen Bioprinters can dispense pure hydrogel formulations and also serve as important components of company's tissue prototyping and manufacturing platform. The Company also intends to use its bioprinting platform as well as 3D technologies to treat its target diseases.